Design, Transfer and Qualification of a Commercially-Scalable Manufacturing Process for CAR-T cells

A UK biotech company is building a factory-scale production line for bespoke cancer therapies that currently cost hundreds of thousands of pounds per patient and take weeks to manufacture. CAR-T therapy works by removing a patient’s own immune cells, genetically reprogramming them to recognise and attack cancer, then infusing them back into the body. Early results in blood cancers have been striking—patients who had exhausted all other options have gone into remission. But the process is slow, expensive, and difficult to scale. Each dose is a one-off, hand-crafted product. This project aims to turn that artisanal process into a repeatable, commercially viable manufacturing system. If successful, the company Autolus could bring CAR-T treatments to common solid tumours—lung, breast, bowel—not just rare blood cancers. That would mean more patients gaining access to a therapy that, for now, remains out of reach for most. The manufacturing innovations could also lower costs and shorten production times, making the entire system more resilient and less dependent on specialist facilities. The project is not fundamental science; it is applied engineering of a biological manufacturing process. The core biology is already proven. The bottleneck is production.